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NST UPDATE 
 
During the last half of the 20th century maternity care changed dramatically, and 
perinatal mortality decreased more than four-fold.  These advances were influenced 
by changes in obstetric surveillance using technology and pharmacology.  I am 
going to discuss technology with electronic fetal monitoring in this issue of Progeny. 
 
Many techniques have been used to identify a fetus that may be at risk for hypoxic 
injury or death.  For years, the only ways to assess a fetus were highly invasive and 
had an increase loss of the fetus, therefore, not widely acceptable.  Since the 1970’s 
the fetus has become more accessible with electronic fetal monitoring (EFM) and 
ultrasound development.  The purpose of antepartum testing is either to validate 
fetal well-being or identify fetal hypoxemia by the presence or absence of one or 
more biophysical parameters and to intervene before permanent injury or death can 
occur whenever possible.  The efficacy to predict perinatal outcomes for different 
populations has not been established.  The nonstress test (NST) evolved from early 
evidence that fetal heart rate (FHR) accelerations were highly associated with fetal 
well-being and that conversely the absence of FHR reactivity was associated with 
increased risk of perinatal mortality.  The NST evolved from the contraction stress 
test (CST).   This was popular in the 1970’s because when a CST was negative, 
there were two accelerations present in 20 minutes.  The NST was technically 
easier, fewer resources were needed, and it could be done in an outpatient or in-
patient setting.   Thus, it became and remains a primary antepartum assessment of 
fetal well-being. 
 
The heart rate of a normal, mature fetus accelerates in response to movement or 
other stimuli, which reflects adequate oxygenation and an intact autonomic nervous 
system.  Accelerations can occur after 20 weeks of gestation but are less frequent 
and of lower amplitude than those occurring later.  The frequency and amplitude of 
acceleration increase with gestational age and evolve into distinct behavior states.  
Some studies suggest that 95% of accelerations begin immediately after movement.  
Larger movements produce greater accelerations.  In contrast, the effects of hypoxia 
on NST results are unclear because the transition from normal to asphyxia is 
unclear.   As fetal compromise continues, movement decreases and eventually 
disappears.   The FHR variability also decreases.   Accelerations become smoother, 
less frequent, and then disappear. 
 
The criteria defined by ACOG for a reactive NST is as follows:  Two accelerations 
with an amplitude of 15 bpm above the baseline and last for 15 seconds within a 20-
minute period.  Less than this is nonreactive.  There may be factors that affect the 
accuracy though, such as, gestational age.  The fetus is more reactive after 32 
weeks, so the significance of early NST’s is not clearly understood.  The fetus may 
be asleep, so you should extend the NST for a minimum of 40 minutes.  Some 
studies state that the fetus is asleep 30% of the time.  Maternal use of medications 
also may affect fetal movement as well as the medical and obstetrical condition of 
the mother.  There may be decelerations during the NST, primarily variable 
decelerations.  Some authorities state they occur in one-half to two-thirds of NST’s.  
They can be caused by position of the umbilical cord, meconium stained amniotic 
fluid, and/or oligohydramnios.  ACOG states,  “A reactive NST with nonrepetitive 
variables lasting less than 30 seconds is not indicative of fetal compromise and 
requires no intervention.”  A nonreactive NST does require further investigation.  
There is a problem of consistency in general agreement on monitoring patterns 
between interobserver and intraobserver.  There is a high false positive rate, which 
means if the NST is nonreactive it does not follow that the fetus is going to have a 
poor outcome.  In fact in one study of term, asphyxiated infants, 63% had no risk 
factors.  In several studies the effects of EFM have shown an increase in C-section 
rates as the most common outcome.  A Meta analysis of 18,000 patients with EFM 
did show a decrease in newborn seizures from 1.1% to 0.8%.  A reactive NST with 
normal amniotic fluid volume is indicative of fetal well-being in 99% of pregnancies.   
The NST is much less reliable when nonreactive. 
 
Conclusion 
The NST continues to be a useful component of antepartum testing and provides 
some information on its own, but several variables need to be measured as well.  
The biophysical profile, especially the amniotic fluid measurement, has become 
another primary means of assessment in the antepartum period.  Umbilical artery 
Doppler velocimetry is another promising measurement to assess fetal well-being.  
The use of fetal pulse oximetry in labor needs more study and is not supported by 
ACOG at this time. 
 
The NST is just one piece of the screening puzzle. 
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R.N.C., Statewide Perinatal Care Program, Department of Pediatrics, 200 Hawkins 
Dr., Iowa City, Iowa  52242-1083  Call (319) 356-2637 or FAX 319-353-8861. 
